Saba Nabil, Khuri Fadlo
Winship Cancer Institute, Emory University, Atlanta, Ga., USA.
Oncology. 2005;68(1):18-22. doi: 10.1159/000084518. Epub 2005 Mar 15.
Newer-generation intravenous bisphosphonates have resulted in the reduction of skeletal-related complications, i.e. skeletal-related events (SREs) such as pain, hypercalcemia, pathologic fractures and spinal cord and nerve compression, as well as improvements in the quality of life in patients with metastatic bone disease who are likely to have a prolonged clinical course. Highly potent, nitrogen-containing bisphosphonates such as zoledronic acid reduce SREs in patients with bone metastases from other solid tumors (including lung cancer). Part one of our review discussed the mechanisms of action by bisphosphonates as well as potential roles for bone markers and imaging in lung cancer. In this article, part two of our review, we examine the economic and clinical impact of bisphosphonates in lung cancer, with a focus on the potential role of newer-generation bisphosphonates in the management of advanced, metastatic bone disease of lung cancer.
新一代静脉用双膦酸盐已使骨相关并发症（即骨相关事件，如疼痛、高钙血症、病理性骨折以及脊髓和神经压迫）减少，同时改善了可能有较长临床病程的转移性骨病患者的生活质量。高效含氮双膦酸盐，如唑来膦酸，可减少其他实体瘤（包括肺癌）骨转移患者的骨相关事件。我们综述的第一部分讨论了双膦酸盐的作用机制以及骨标志物和影像学在肺癌中的潜在作用。在本文，即我们综述的第二部分，我们研究双膦酸盐在肺癌中的经济和临床影响，重点关注新一代双膦酸盐在肺癌晚期转移性骨病管理中的潜在作用。
